argenx SE (FRA:1AE) EBIT: €1,294 Mil (TTM As of Mar. 2026)

What is argenx SE EBIT?

argenx SE FRA:1AE -1.02% 78 EBIT is €1,294 Mil as of Mar. 2026. GuruFocus rates FRA:1AE with a GF Score™ of 78/100 and a GF Value™ of €1,204.08 (Significantly Undervalued). The stock has 5 warning signs investors should review.

argenx SE's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €369 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €1,294 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. argenx SE's annualized ROC % for the quarter that ended in Mar. 2026 was 38.66%. argenx SE's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 167.88%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. argenx SE's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.89%.

argenx SE (FRA:1AE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

argenx SE's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	1363.24 * ( 1 - 14.08% )	/	( (3029.721	+	0)	/ 1 )
=	1171.295808	/	3029.721
=	38.66 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7415.024	-	593.51	-	( 3791.793	-	max(0, 1127.439	-	5891.835	+	3791.793	))
=	3029.721

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

argenx SE's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1477.42	/	( ( (41.203 + max(838.82, 0))	+	(0 + max(0, 0)) )	/	1 )
=	1477.42	/	( ( 880.023	+	0 )	/	1 )
=	1477.42	/	880.023
=	167.88 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1272.094	+	404.395	+	280.519)	-	(593.51	+	0	+	524.678)
=	838.82

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

argenx SE's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	1294.386	/	44749.248
	=	2.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

argenx SE EBIT Related Terms

argenx SE EBIT Historical Data

* Premium members only.

The historical data trend for argenx SE's EBIT can be seen below:

argenx SE EBIT Chart

argenx SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-352.80

-686.40

-278.39

83.70

1,095.42

argenx SE Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															187.78	250.15	329.76	345.12	369.36

FRA:1AE vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, argenx SE's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

argenx SE EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where argenx SE's EV-to-EBIT falls into.

Save Embed

78GF Score

argenx SE FRA:1AE

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

argenx SE EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,294 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of €1,294 Mil mean?

argenx SE (FRA:1AE) has a EBIT of €1,294 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on argenx SE.

Is argenx SE's EBIT too high?

argenx SE's current EBIT is €1,294 Mil. Overall, argenx SE has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does argenx SE's EBIT compare to VRTX and REGN?

argenx SE's EBIT of €1,294 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on argenx SE. argenx SE's current EBIT is €1,294 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is argenx SE stock overvalued right now?

Based on GuruFocus' analysis, argenx SE (FRA:1AE) is currently considered Significantly Undervalued. The stock's GF Value™ is €1,204.08, compared to a current price of €753.20 — trading 37.4% below its estimated fair value. The current EBIT is €1,294 Mil. argenx SE's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For argenx SE (FRA:1AE), the current EBIT is €1,294 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is argenx SE (FRA:1AE) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of €753.20 is trading 37.4% below its estimated GF Value™ of €1,204.08. GuruFocus considers argenx SE to be Significantly Undervalued.

Key valuation signals for FRA:1AE:

EBIT: €1,294 Mil
GF Value™: €1,204.08 vs. price of €753.20 (37.4% below fair value)
GF Score™: 78/100 with 5 warning signs

No single metric tells the full story. See the FRA:1AE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

argenx SE Business Description

Industry Healthcare Biotechnology

Comparable Companies XBRU:UCB XBRU:TUB XBRU:ONWD XBRU:HYL XBRU:ALEMS XBRU:CYAD XBRU:OXUR VRTX REGN XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270 RPRX BNTX INSM ROIV INCY

Other Exchanges ARGX:USA ARGNF:USA ARGXb:UK 0QW0:UK A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website https://www.argenx.com

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

78GF Score

Get the complete analysis for FRA:1AE

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€753.20

Price

€1,204.08

GF Value

View FRA:1AE Analysis

See EBIT data for all stocks →